Is one vaccine dose enough for individuals who have recovered from a SARS-CoV-2 infection?
Research stemming from the CITF-funded RECOVER study, published in Frontiers in Immunology, indicates that a two-dose primary series of vaccination is paramount for protection against COVID-19, even for those who were previously infected. Individuals who did not experience symptoms during their SARS-CoV-2 infection and had no antibodies to SARS-CoV-2 (negative serostatus) prior to vaccination show weaker immune responses to each vaccine dose than their symptomatic counterparts.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed